| Name | Kinkead Pharmacy Inc |
|---|---|
| Organization Name | Kinkead Pharmacy Inc |
| Location | 105 S Allen St, Centralia, Missouri 65240 |
| Type | Community/Retail Pharmacy |
| Phone | (573) 682-2155 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
The type of primary insurance patients carry affects outcomes of cardiac valve operations in the United States according to a study in the May issue of the Journal of the American College of Surgeons.
Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced.
B cell acute lymphoblastic leukaemia, or B-ALL, is the most common tumour disease in children and also occurs in adults. It develops when signalling pathways in immature B cells, or pre-B cells, are dysregulated. Prof. Dr. Markus Müschen from the University of California in San Francisco, USA, and his team worked together with the BIOSS researchers Prof. Dr. Hassan Jumaa and Prof. Dr. Michael Reth to find a new approach for treating the B-ALL tumour disease.
New scientific evidence on how feedback from the eye affects visual development may lead to more effective approaches to treating myopia (nearsightedness) in children, reports a paper in the September issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Low levels of both oxygen and the powerful blood vessel dilator nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report.
› Verified 4 days ago
| NPI Number | 1033255179 |
| Organization Name | KINKEAD PHARMACY, INC. |
| Type | Community/Retail Pharmacy |
| Address | 105 S Allen St, Centralia, MO 65240 |
| Phone Number | 573-682-2155 |
News Archive
The type of primary insurance patients carry affects outcomes of cardiac valve operations in the United States according to a study in the May issue of the Journal of the American College of Surgeons.
Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced.
B cell acute lymphoblastic leukaemia, or B-ALL, is the most common tumour disease in children and also occurs in adults. It develops when signalling pathways in immature B cells, or pre-B cells, are dysregulated. Prof. Dr. Markus Müschen from the University of California in San Francisco, USA, and his team worked together with the BIOSS researchers Prof. Dr. Hassan Jumaa and Prof. Dr. Michael Reth to find a new approach for treating the B-ALL tumour disease.
New scientific evidence on how feedback from the eye affects visual development may lead to more effective approaches to treating myopia (nearsightedness) in children, reports a paper in the September issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Low levels of both oxygen and the powerful blood vessel dilator nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report.
› Verified 4 days ago
News Archive
The type of primary insurance patients carry affects outcomes of cardiac valve operations in the United States according to a study in the May issue of the Journal of the American College of Surgeons.
Zeltia announces today that its pharmaceutical division PharmaMar will start a Phase III trial with PM1183 in combination with doxorubicin against topotecan in SCLC, given the activity observed in an interim analysis of an ongoing Phase Ib trial. The results of this study will be presented at a prominent international cancer meeting this year, which will be soon announced.
B cell acute lymphoblastic leukaemia, or B-ALL, is the most common tumour disease in children and also occurs in adults. It develops when signalling pathways in immature B cells, or pre-B cells, are dysregulated. Prof. Dr. Markus Müschen from the University of California in San Francisco, USA, and his team worked together with the BIOSS researchers Prof. Dr. Hassan Jumaa and Prof. Dr. Michael Reth to find a new approach for treating the B-ALL tumour disease.
New scientific evidence on how feedback from the eye affects visual development may lead to more effective approaches to treating myopia (nearsightedness) in children, reports a paper in the September issue of Optometry and Vision Science, official journal of the American Academy of Optometry. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.
Low levels of both oxygen and the powerful blood vessel dilator nitric oxide appear to have an unfortunate synergy for patients with sickle cell disease, researchers report.
› Verified 4 days ago
Kinkead Pharmacy Inc Type: Community/Retail Pharmacy Location: 105 S Allen St, Centralia, Missouri 65240 Phone: (573) 682-2155 |